Nov 17, 2020 | biosimilars, innovation, oncology |
here’s how biologics have become an important part in the cancer landscape, providing better outcomes for some patients . because they are made from living organisms biologics can not be exactly copied [generics]. the complex manufacturing process of biologics...
Jan 13, 2020 | biosimilars, health policy, oncology, oncopolicy |
last december, the canadian institute for health information published statistics on drug spending, finding that in 2018 approximately 40% of drug spending was spent on 2% of beneficiaries. of this 2%, three out of five individuals used a drug therapy that cost...
Aug 29, 2019 | biosimilars, innovation, oncology |
biosimilars provide an opportunity to manage the incoming innovation in oncology and to create a more sustainable healthcare system. but this can only be realized if savings generated from the use of biosimilars is re-allocated into cancer drug budgets [and not into a...
Jun 21, 2019 | biosimilars, innovation, oncology |
the cancer collaborative hosted a webinar on June 19 2019 with jatinder harchowal from the NHS whereby he provided insight into the NHS’ experience implementing biosimilars in oncology. jatinder spoke during the webinar about the work that was done in england...
May 30, 2019 | biosimilars, innovation, oncology |
biosimilars aren’t coming, they’re here. in 2010 health canada published the HC Guidance document: information and submission requirements for biosimilar biologic drugs. in April 2018, health canada approved the first oncology biosimilar. here we are today, may 2019-...
